(19)
(11) EP 2 630 956 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
17.07.2019 Bulletin 2019/29

(45) Mention of the grant of the patent:
27.02.2019 Bulletin 2019/09

(21) Application number: 11834585.9

(22) Date of filing: 17.10.2011
(51) International Patent Classification (IPC): 
A61K 9/22(2006.01)
A61K 9/16(2006.01)
A61K 31/44(2006.01)
A61K 31/436(2006.01)
 A61K 47/38(2006.01)
A61K 9/20(2006.01)
A61K 9/50(2006.01)
(86) International application number:
PCT/KR2011/007708
(87) International publication number:
WO 2012/053785 (26.04.2012 Gazette 2012/17)

(54)

SUSTAINED-RELEASE PELLETS CONTAINING TACROLIMUS AS AN ACTIVE INGREDIENT

RETARDIERTE PELLETS MIT TACROLIMUS ALS WIRKSTOFF

PASTILLES À LIBÉRATION PROLONGÉE CONTENANT DU TACROLIMUS À TITRE DE PRINCIPE ACTIF

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 19.10.2010 KR 20100101778

(43) Date of publication of application:
28.08.2013 Bulletin 2013/35

(73) Proprietors:
  • Lee, Hee-Yub
    Suwon-si, Gyeonggi-do 441-744 (KR)
  • Reyon Pharmaceutical Co., Ltd
    Seoul 06176 (KR)

(72) Inventor:
  • LEE, Hee-Yub
    Suwon-si, Gyeonggi-do 441-744 (KR)

(74) Representative: Arends, William Gerrit 
Marks & Clerk LLP 15 Fetter Lane
London EC4A 1BW
London EC4A 1BW (GB)


(56) References cited: : 
EP-A1- 2 119 442
KR-A- 20100 060 766
US-A1- 2008 181 947
US-A1- 2010 086 592
 EP-A2- 1 974 722
KR-B1- 100 539 706
US-A1- 2009 011 018
   
     
    Remarks:
    The file contains technical information submitted after the application was filed and not included in this specification
     
    Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).